Daniel Eek
Overview
Explore the profile of Daniel Eek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schuiveling M, Liu H, Eek D, Breimer G, Suijkerbuijk K, Blokx W, et al.
Gigascience
. 2025 Feb;
14.
PMID: 39970004
Background: Melanoma is an aggressive form of skin cancer in which tumor-infiltrating lymphocytes (TILs) are a biomarker for recurrence and treatment response. Manual TIL assessment is prone to interobserver variability,...
2.
Troldborg A, Remkus L, Eek D, Deleuran B
Lupus
. 2024 Jun;
33(9):962-973.
PMID: 38901042
Anifrolumab is a new therapeutic approach for individuals with systemic lupus erythematosus (SLE) directed at blocking the type 1 interferon pathway. Despite the expanding body of literature on Anifrolumab, an...
3.
Parodis I, Haugli-Stephens T, Stephens T, Dominicus A, Eek D, Sjowall C
Rheumatology (Oxford)
. 2024 Feb;
64(2):639-647.
PMID: 38402496
Objectives: Beyond prevention of organ damage, treatment goals in SLE include optimization of health-related quality of life (HRQoL). The Lupus Low Disease Activity State (LLDAS) has received increasing attention as...
4.
Liljeroos M, Agvall B, Eek D, Fu M
Patient Prefer Adherence
. 2023 Aug;
17:1935-1947.
PMID: 37581194
Purpose: Qualitative studies that highlight the patient perspective of heart failure (HF) and its impact on the lives of patients are limited. Our study objective was to describe the patient's...
5.
Eek D, Halling K, Flood E, Blowfield M, Meyers O, Venerus M, et al.
Drug Saf
. 2021 Jun;
44(10):1059-1072.
PMID: 34129206
Introduction: There is a need to understand how patients assess perceived benefits and risks of treatments. Objectives: The study aimed to (i) elucidate how patients evaluate treatment experiences and (ii)...
6.
Eek D, Ivanescu C, Corredoira L, Meyers O, Cella D
J Patient Rep Outcomes
. 2021 Mar;
5(1):27.
PMID: 33709202
Purpose: Fatigue is a prominent symptom in individuals with chronic lymphocytic leukemia (CLL). This work evaluates the content validity and psychometric properties of the Functional Assessment of Chronic Illness Therapy-Fatigue...
7.
Eek D, Blowfield M, Krogh C, Chung H, Eyre T
Patient
. 2020 Aug;
14(1):75-87.
PMID: 32808103
Background And Objective: Understanding the patient experience is important for identifying the unmet need in chronic lymphocytic leukemia. The current study aimed to develop a comprehensive chronic lymphocytic leukemia conceptual...
8.
Condon D, Chapman R, Shaunfield S, Kallen M, Beaumont J, Eek D, et al.
Qual Life Res
. 2019 Nov;
29(3):745-753.
PMID: 31701432
Purpose: To evaluate the influence of recall periods on the assessment of physical function, we compared, in cancer and general population samples, the standard administration of PROMIS Physical Function items...
9.
Martin M, Halling K, Eek D, Reaney M
Patient
. 2019 Nov;
13(2):189-200.
PMID: 31691205
Background: Understanding the patient's perception of their disease is vital for guiding care decisions. The current study aimed to identify the most predominant experiences in women diagnosed with, and treated...
10.
Butler S, Eek D, Ring L, Gordon A, Karlsten R
Scand J Pain
. 2018 Nov;
19(2):327-335.
PMID: 30407914
Background and aims The RELIEF (Real Life) study by AstraZeneca was designed as an observational study to validate a series of Patient Reported Outcome (PRO) questionnaires in a mixed population...